Overview
MARA Rating completed 17 new Reimbursement Risk Assessments in June 2026. The assets span nine therapeutic areas: oncology, obesity, neurology, rare disease, pulmonology, cardiology, immunology, hepatology, and infectious disease.
Each assessment applies the same structured 10-domain framework — calibrated against historical HTA outcomes across the US, EU4, UK, and Japan — regardless of therapeutic area, company size, or development stage. The result is a standardized risk signal that can be compared across assets, portfolios, and time.
This article presents the full June 2026 batch, organized by reimbursement risk band.
Why Risk Band Distribution Matters
The distribution of ratings across a batch is not incidental. It reflects the current state of evidence and economic positioning across an entire development cohort.
In this batch: one asset at A (Strong), twelve at B++ (Marginal), four at B+ (Very Weak). No assets reached A+ or above. None fell to B or C.
The concentration in the Marginal band is consistent with broader patterns observed across recent MARA batches. It is not the result of unusually weak science. It reflects a structural gap that repeats across therapeutic areas: clinical efficacy is rarely the gating issue today. The gating issues are comparative positioning, economic modeling maturity, and the completeness of the evidence package as assessed by payers — not clinicians. Assets with credible clinical signals are stalling at B++ because the economic case has not been built, or because active comparator data are missing.
That gap is where reimbursement risk concentrates. And it is where decisions made now — on trial design, pricing strategy, and HTA sequencing — will determine access outcomes.
A — Strong
Solid evidence profile. Access expected with standard conditions.
Wegovy / Semaglutide — Weight Management in Adults with Obesity or Overweight with at Least One Comorbidity
Semaglutide is the only asset in this batch to reach A (Strong). The evidence base is consistent and replicable across multiple phase 3 trials, with a mean body-weight reduction of -14.9% at 68 weeks versus -2.4% with placebo. Cost-effectiveness is marginal at an estimated ICER of $66,355/QALY but remains defensible under common payer thresholds. The rating reflects a mature, well-documented evidence profile in a therapeutic area where payer scrutiny is intensifying — not declining.
B++ — Marginal
Reimbursement still achievable. Outcome is sensitive to pricing, positioning, and evidence evolution.
Twelve of the seventeen assets fall in this band. A B++ rating does not signal failure. It signals a finely balanced position — one where the access outcome is not yet determined by the evidence alone, and where pricing strategy, comparative data, and negotiation positioning will be decisive.
BAXFENDY / baxdrostat — Resistant Hypertension
Two phase 3 trials (BaxHTN, Bax24) demonstrated placebo-corrected blood pressure reductions of 9.8 and 14.0 mmHg respectively. The clinical signal is meaningful. No public cost-effectiveness model exists, and long-term cardiovascular outcome data remain absent. The economic case has not yet been built.
Belumosudil — Chronic Graft-Versus-Host Disease After Failure of Prior Systemic Therapy
The ROCKstar trial showed a 75% overall response rate in a setting with limited therapeutic alternatives. The evidence is single-arm and uncontrolled, which limits the strength of superiority claims. NICE modeling suggests acceptable ICERs (£2,976–£15,226/QALY), though uncertainty remains high across jurisdictions.
HEPCLUDEX / bulevirtide — Chronic Hepatitis Delta Without Cirrhosis or With Compensated Cirrhosis
MYR301 demonstrated a combined primary endpoint in 45–48% of patients versus 2% in the control arm. Cost-effectiveness estimates diverge sharply across jurisdictions — NICE modeling falls within acceptable range (~£27,000/QALY), while NCPE found the ICER unacceptably high (€193,273/QALY). Country-by-country pricing risk is the dominant variable.
Xocova (ensitrelvir) — Post-Exposure Prophylaxis of COVID-19 in Adults
Phase 3 SCORPIO-PEP data show a 67% relative risk reduction versus placebo, with a 6.1 percentage point absolute risk reduction. The clinical case is supportable. No cost-effectiveness evidence has been submitted to any major HTA body, leaving the economic profile entirely open — a significant liability in price-sensitive markets.
JASCAYD (nerandomilast) — Idiopathic Pulmonary Fibrosis / Progressive Pulmonary Fibrosis
Phase 3 trials demonstrated meaningful preservation of lung function versus placebo (FVC decline differences of 48–64 mL) in a disease with limited treatment options. No cost-utility model is publicly available. The economic evidence package needs to be developed before HTA submission.
Foundayo / orforglipron — Overweight and Obesity
Phase 3 data show meaningful weight loss versus placebo, but no head-to-head comparison against semaglutide or tirzepatide has been conducted. In a class now anchored by those reference points, the absence of active comparator data creates direct HTA vulnerability. A conference-poster ICER of $161,466/QALY further weakens the current economic position.
Redemplo / plozasiran — Familial Chylomicronemia Syndrome
The PALISADE trial showed a median triglyceride reduction of -80% versus -17% for placebo. The primary endpoint is a biochemical surrogate rather than a clinical outcome, which will attract HTA scrutiny. No cost-effectiveness model has been published.
Tryngolza / olezarsen — Familial Chylomicronemia
The BALANCE trial showed a -42.5 percentage point placebo-adjusted triglyceride reduction. Evidence is limited to a single phase 3 study with a small sample and no long-term controlled data. No cost-effectiveness evidence is available.
Remibrutinib — Chronic Spontaneous Urticaria After Inadequate H1-Antihistamine Response
Two phase 3 trials demonstrated statistically significant UAS7 improvements versus placebo. Long-term durability data and direct comparisons against omalizumab — the established biological in this class — are not yet available. One conference abstract indicates lack of cost-effectiveness versus cetirizine.
Tarlatamab — Relapsed Extensive-Stage Small Cell Lung Cancer After Two or More Prior Lines
DeLLphi-301 reported a 40% objective response rate and 9.7-month median duration of response — clinically meaningful in a historically refractory setting. The absence of a randomized comparator arm limits HTA interpretability. NICE and CDA-AMC analyses place the ICER above commonly accepted thresholds, even with commercial arrangements factored in.
Tolebrutinib — Non-Relapsing Secondary Progressive Multiple Sclerosis
The HERCULES trial demonstrated a hazard ratio of 0.69 for disability progression — statistically significant, clinically modest, with mixed secondary endpoints. ICER modeling reached $3.4 million per QALY, reflecting a placeholder price rather than a settled commercial position. The magnitude of economic risk is material if pricing is not negotiated substantially downward.
Vepdegestrant — Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer After Endocrine Treatment
VERITAC-2 showed a meaningful PFS benefit in the ESR1-mutated subgroup (5.0 vs 2.1 months versus fulvestrant). The overall population result was not statistically significant, creating a positioning challenge for HTA submissions. No public cost-effectiveness model exists.
B+ — Very Weak
Significant access barriers identified. Restrictions or delays are probable without major evidence or pricing adjustments.
Camizestrant — ER-Positive, HER2-Negative Breast Cancer
Phase 2 SERENA-2 data show PFS improvements versus fulvestrant (7.2–7.7 months vs 3.7 months). The evidence base is open-label and phase 2 — insufficient for most HTA bodies to assess with confidence. No economic evidence has been published. The rating reflects the gap between a promising signal and a defensible submission package.
Paltusotine — Maintenance Treatment of Acromegaly in Adults
PATHFNDR-1 demonstrated that 83.3% of patients maintained IGF-I control versus 3.6% on placebo. The pivotal limitation is the absence of direct comparison against injectable somatostatin analogues — the established standard of care. HTA bodies are unlikely to accept a placebo-controlled maintenance trial as primary evidence in an indication where injectable alternatives already perform well. No cost model is available.
Pivekimab sunirine-pvzy — Blastic Plasmacytoid Dendritic Cell Neoplasm
A complete remission rate of 69.7% in treatment-naive patients is clinically significant in an ultra-rare disease with no approved alternatives. The evidence derives from a single-arm phase 1/2 study (CADENZA). The rare-disease context provides some HTA flexibility, but the uncontrolled design and absence of any economic modeling constitute material risks that cannot be offset by unmet need alone.
Sonrotoclax — Relapsed or Refractory Mantle Cell Lymphoma After Prior BTK Inhibitor
Phase 1/2 data report a 52% overall response rate and 16% complete response rate in a post-BTK setting with limited alternatives. The evidence is early-stage and uncontrolled. No cost-effectiveness data exist. The rating reflects a credible mechanism with an evidence base not yet ready for HTA defense.
Methodological Note
All ratings in this batch were produced using the MARA 10-domain scoring framework, calibrated against historical HTA outcomes across NICE (UK), G-BA (Germany), HAS (France), and ICER (US). Scores are derived from publicly available clinical, regulatory, and economic data only. Inter-rater consistency — the same asset assessed independently producing the same score — is enforced as a structural requirement of the framework.
These assessments reflect reimbursement probability under HTA frameworks. They are not regulatory opinions and do not reflect commercial viability independent of market access.
Keep following us
MARA will continue to monitor material evidence events and adjust the reimbursement risk signal accordingly.
Browse the full MARA Ratings Catalogue → mararating.com/mara-ratings-list
MARA Rating Company AG | Independent Reimbursement Risk Assessments | mararating.com